Postoperative chemo-endocrine treatment with mitomycin C, tamoxifen, and UFT is effective for patients with premenopausal estrogen receptor-positive stage II breast cancer

Breast Cancer Research and Treatment

Volumn 56, Issue 2, 1999, Pages 113-124

  Sugimachi, Keizo ^a   Maehara, Yoshihiko ^a   Akazawa, Kohei ^a   Nomura, Yasuo ^b   Eida, Kazuyuki ^c   Ogawa, Michio ^d   Konaga, Eiji ^e   Tanaka, Noriaki ^f   Toge, Tetsuya ^g   Dohi, Kiyohiko ^h   Noda, Shoichi ⁱ   Maeda, Masazumi ^j   Monden, Yasumasa ^k  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

^c Nagasaki Red Cross Hospital   (Japan)

^d KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^e IWAKUNI NATIONAL HOSPITAL   (Japan)

^f OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^g HIROSHIMA UNIVERSITY   (Japan)

^h HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

ⁱ NATIONAL HOSPITAL ORGANIZATION BEPPU MEDICAL CENTER   (Japan)

^j KAGAWA UNIVERSITY   (Japan)

^k UNIVERSITY OF TOKUSHIMA   (Japan)

more..

Author keywords

Breast cancer; Estrogen receptor; Mitomycin C; Postoperative chemotherapy; Tamoxifen; UFT

Indexed keywords

ESTROGEN RECEPTOR; MITOMYCIN C; TAMOXIFEN; TEGAFUR; UFT;

ADULT; AGED; ANOREXIA; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LIVER DYSFUNCTION; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MASTECTOMY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NAUSEA; ORAL DRUG ADMINISTRATION; POSTOPERATIVE CARE; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

EID: 0032698405     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1006221425652     Document Type: Article

References (41)

1. Consensus conference: Adjuvant chemotherapy for breast cancer. JAMA 254: 3461-3463, 1985
2. Pritchard KI: Current status of adjuvant endocrine therapy for resectable breast cancer. Semin Oncol 14: 23-33, 1987
3. Goldhirsch AG, Wood WC, Senn H-J, Glick JH, Gelber RD: Meeting highlights: International consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 87: 1441-1445, 1995
4. Patterson I, Furr B, Wakeling A, Battersby L: The biology and physiology of 'Nolvadex' *(tamoxifen) in the treatment of breast cancer. Breast Cancer Res Treat 2: 363-374, 1982
5. Early Breast Cancer Trialists' Collaborative Group: Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: An overview of 61 randomized trials among 28,806 women. New Engl J Med 319: 1681-1691, 1988
6. Fisher B, Redmond C, Legault-Poisson S, Dimitrov NV, Brown AM, Wickerham DL, Wolmark N, Margolese RG, Bowman D, Glass AG, Kardinal CG, Robidoux A, Jochimsen P, Cronin W, Deutsch M, Fisher ER, Myers DB, Hoehn JL: Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: Results from the National Surgical Adjuvant Breast and Bowel Projects B-16. J Clin Oncol 8: 1005-1018, 1990
7. Early Breast Cancer Trialist's Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy, 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339: 1-15, 71-84, 1992
8. Bonadonna G, Valagussa P, Moliterini A, Zambetti M, Brambilla C: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. New Engl J Med 332: 901-906, 1995
9. Yoshida M, Murai H, Miura H: Chemotherapy with mitomycin-C and cyclophosphamide adjuvant to surgery for breast cancer. Jpn J Clin Oncol 9: 27-34, 1979
10. Koyama H, Wada T, Takahashi Y, Nishizawa Y, Iwanaga T, Aoki Y, Terasawa T, Kosaki G, Kajita A, Wada A: Surgical adjuvant chemotherapy with mitomycin C and cyclophosphamide in Japanese patients with breast cancer. Cancer 46: 2373-2379, 1980
11. Ikenaka K, Shirasaka T, Kitano S, Fujii S: Effect of uracil on metabolism of 5-fluorouracil in vitro. Gann 70: 353-359, 1979
12. Machara Y, Nagayama S, Okazaki H, Nakamura H, Shirasaka T, Fujii S: Metabolism of 5-fluorouracil in various human normal and tumor tissues. Gann 72: 824-827, 1981
13. Etienne MC, Chéradame S, Fischel JL, Formento FP, Dassonville O, Renée N, Schneider M, Thyss A, Demard F, Milano G: Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 13: 1663-1670, 1995
14. Heggie GD, Sommadossi J-P, Cross DS, Huster WJ, Diasio RB: Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47: 2203-2206, 1987
15. Allegra JC, Lippman ME, Thompson EB, Simon R: An association between steroid receptors and response to cytotoxic chemotherapy in patients with metastatic breast cancer. Cancer Res 38: 4299-4304, 1978
16. Lippman ME, Allegra JC, Thompson EB, Simon R, Barlock A, Green L, Huff KK, Do HMT, Aitken SC, Warren R: The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. New Engl J Med 298: 1223-1228, 1978
17. Machara Y, Emi Y, Sakaguchi Y, Kusumoto T, Kakeji Y, Kohnoe S, Sugimachi K: Estrogen-receptor-negative breast cancer tissue is chemosensitive in vitro compared with estrogen-receptor-positive tissue. Eur Surg Res 22: 50-56, 1990
18. Wada T, Koyama H, Nishizawa Y, Takahashi Y, Fukuda I, Iwanaga T, Terasawa T: Chemo-endocrine therapy for advanced breast cancer-A combined treatment with tamoxifen and FT-207. J Jpn Soc Cancer Ther 16: 51-55, 1981 (in Japanese with English abstract)
19. Morimoto T, Ogawa M, Orita K, Sugimachi K, Toge T, Dohi K, Nomura Y, Monden Y, Ogawa N: Postoperative adjuvant randomized trial comparing chemoendocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5-year results from the Nishinihn cooperative study group of adjuvant chemoendocrine therapy for breast cancer (ACETBC) of Japan. Eur J Cancer 32A: 235-242, 1996
20. Fujii S, Ikenaka K, Fukushima M, Shirasaka T: Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. Gann 69: 763-772, 1978
21. Fujii S, Kitano S, Ikenaka K, Shirasaka T: Effect of coadministration of uracil or cytosine on the antitumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents. Gann 70: 209-214, 1979
22. Ota K, Taguchi T, Kimura K, Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 22: 333-338, 1988
23. Tashiro H, Nomura Y and Ohsaki A: A double blind comparative study of tegafur (FT) and UFT (a combination of tegafur and uracil) in advanced breast cancer. Jpn J Oncol 24: 212-217, 1994
24. Baum M, Brinkley DM, Dossett JA, McPherson K, Patterson JS, Rubens RD, Smiddy FG, Stoll BA, Wilson A, Lea JC, Richards D, Ellis SH: Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Lancet 1(8319): 257-261, 1983
25. Japanese Breast Cancer Society: The general rules for clinical and pathological recording of breast cancer. Jpn J Surg 19: 612-632, 1989
26. Japan Society for Cancer Therapy: Criteria for the evaluation of the clinical effects of solid cancer chemotherapy. J Jpn Soc Cancer Ther 28: 101-130, 1993
27. Dixon WJ (ed): BMDP Statistical Software. University of California Press Berkeley, CA, 1988
28. Rosner B: Fundamentals of Biostatistics. Duxbury Press, New York, 1995
29. Cox DR: Regression models and life tables. J Royal Statist Soc Series B 34: 187-220, 1972
30. Izuo M: Clinicopathological features of recurrent breast cancer. Jpn J Cancer Chemother 12: 412-420, 1985 (in Japanese with English abstract).
31. Rossi A, Bonadonna G, Valagussa P, Veronesi U: Multimodal treatment in operable breast cancer: five-year results of the CMF programme. Br Med J 282: 1427-1431, 1981
32. Fisher B, Fisher ER, Redmond C: Ten-year results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trial evaluating the use of L-phenylalamine mustard (L-PAM) in the management of primary breast cancer. J Clin Oncol 4: 929-941, 1986
33. Budzar AU, Kau SW, Smith TL, Hortobagyi GN: Ten-year results of FAC adjuvant chemotherapy trial in breast cancer. Am J Clin Oncol 12: 123-128, 1989
34. Richards MA, O'Reilly SM, Howell A, George WD, Fentiman IS, Chaudary MA, Crowther D, Rubens RD: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with axillary node-positive breast cancer: An update of the Guy's/Manchester trial. J Clin Oncol 8: 2032-2039, 1990
35. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339: 71-85, 1992
36. Osborne CK, Hobbs K, Clark GM: Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res 45: 584-590, 1985
37. Conte PF, Frashini G, Alama A, Nicolin A, Corsaro E, Canavese G, Rosso R, Drewinko B: Chemotherapy following estrogen induced expansion of the growth fraction of human breast cancer. Cancer Res 45: 5926-5930, 1985
38. Hug V, Johnston D, Finders M, Hortobagyi G: Use of growth stimulatory hormones to improve the in vitro therapeutic index of duxorubicin for human breast tumors. Cancer Res 46: 147-152, 1986
39. Elston CW, Gresham GA, Rao GS, Zebro T, Haybitlle JL, Houghton J, Kearney G: The cancer research campaign (King's/Cambridge) trial for early breast cancer: Clinicopathological aspects. Br J Cancer 45: 655-669, 1982
40. Early breast cancer trialist's collaborative group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451-1467, 1998
41. Tormey DC, Gray R, Gilchrist K, Grage T, Carbone PP, Wolter J, Woll JE, Cummings FJ: Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. Cancer 65: 200-206, 1990